Polyomavirus‐driven Merkel cell carcinoma: Prospects for therapeutic vaccine development

Abstract excerpt

Great strides have been made in cancer immunotherapy including the breakthrough successes of anti-PD-(L)1 checkpoint inhibitors. In Merkel cell carcinoma (MCC), a rare and aggressive skin cancer, PD-(L)1 blockade is highly effective. Yet, ~50% of patients either do not respond to therapy or develop PD-(L)1 refractory disease and, thus, do not experience long-term benefit. For these patients, additional or...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antenna Design and Analysis
• Share to Full-Duplex Wireless Communications
• Share to Polyomavirus and related diseases